4D pharma appoints John Doyle as Chief Financial Officer

Rhea-AI Summary

4D pharma plc announces the appointment of John Doyle as its new Chief Financial Officer (CFO). Mr. Doyle, with over 15 years of experience in financial operations and investor relations within public healthcare companies, aims to drive the company's financial strategy as it continues to advance its Live Biotherapeutic programs. CEO Duncan Peyton expressed enthusiasm about Doyle's expertise, particularly following the company's NASDAQ listing in 2021. 4D pharma is focused on developing innovative drugs derived from the microbiome to address unmet medical needs.

Positive

• John Doyle's extensive 15 years of experience in financial operations could strengthen financial strategy and investor relations.
• Doyle's background in leading healthcare companies aligns well with the company's growth stage following its NASDAQ listing.

Negative

• Concerns might arise regarding the continuity and integration of Doyle into the existing team due to his recent appointment.

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces the appointment of John Doyle as Chief Financial Officer (CFO). Mr. Doyle brings over 15 years of experience leading and developing the financial operations, strategy and investor relations functions at public healthcare companies.

“We are delighted to welcome John to 4D pharma at this exciting stage of the company’s growth, following our NASDAQ listing in 2021,” said Duncan Peyton, Chief Executive Officer of 4D pharma. “John’s extensive financial experience in diverse healthcare organizations and transformational events will be invaluable as 4D pharma continues to make progress in the clinic on multiple fronts with our Live Biotherapeutic programs.”

“I am honored to join a company that is committed to delivering a revolutionary class of medicines by harnessing bacteria from the microbiome,” said John Doyle, Chief Financial Officer of 4D pharma. “The 4D pharma team has built an impressive pipeline across key areas of high unmet need and I am excited for the opportunity to execute on the company’s growth strategy and financial goals.”

Mr. Doyle joins 4D pharma after serving as CFO at Chiasma Inc., a publicly traded biopharmaceutical company acquired by Amryt Pharma in 2021. Prior to Chiasma, John was Vice President of Finance and Investor Relations at Verastem Inc., a publicly traded biopharmaceutical company. Prior to joining Verastem in February 2018, he served as Head of Financial Planning & Analysis at SimpliVity Corp., a software company that was acquired by Hewlett Packard Enterprises in February 2017. Before that, Mr. Doyle was Director of Business Unit Financial Planning & Analysis, Early Phase Division, at PAREXEL, a publicly traded pharmaceutical contract research organization. Earlier in his career, he served in increasingly senior financial planning and analysis roles at Hologic, Inc., a publicly traded provider of medical diagnostic, surgical and imaging products. Mr. Doyle holds a B.S. in finance from the University of Massachusetts.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20220103005054/en/

4D pharma

Investor Relations: ir@4dpharmaplc.com

Singer Capital Markets - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency

6 Degrees

Lynne Dardanell +1-336-202-9689

ldardanell@6degreespr.com

Source: 4D pharma plc

FAQ

What is the significance of John Doyle's appointment as CFO of LBPS?

John Doyle's appointment is significant as he brings over 15 years of financial expertise in healthcare, which will help guide 4D pharma's financial strategy during its growth phase.

How does John Doyle's experience impact 4D pharma's future?

Doyle's experience in public healthcare and financial operations is expected to enhance investor relations and contribute positively to 4D pharma's development of Live Biotherapeutics.

When was John Doyle appointed CFO of LBPS?

John Doyle was appointed CFO of 4D pharma plc (LBPS) as announced in the recent press release.

What should investors expect from 4D pharma with the new CFO?

Investors can expect a focused approach on financial strategy and possibly improved investor communications under Doyle's leadership.